Form 8-K uniQure N.V. For: Jun 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'
June 17, 2026 1:27 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More
uniQure BV (QURE) PT Raised to $71 at Stifel
June 17, 2026 9:31 AM EDTStifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a Buy rating.
The analyst comments "We're reiterating our Buy rating on QURE and raising our TP to $71, on the back of a positive and welcome surprise around FDA's ~180 on the regulatory path for AMT-130 (LINK). Bottom line: we now model a slightly greater than 50%... More
